Stoke Therapeutics, Inc. (STOK)
NASDAQ: STOK · Real-Time Price · USD
28.86
-1.18 (-3.93%)
At close: Jul 31, 2026, 4:00 PM EDT
28.80
-0.06 (-0.21%)
After-hours: Jul 31, 2026, 7:45 PM EDT
Stoke Therapeutics Stock Forecast
Stock Price Forecast
According to 13 analysts polled by S&P Global, Stoke Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $45.82. The average 1-year stock price forecast is 58.77% higher than the current stock price, while the lowest is $35 (+21.28%) and the highest is $60 (+107.90%).
Price Target: $45.82 (+58.77%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Stoke Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 11 | 11 | 11 | 11 | 11 | 12 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 12 | 12 | 12 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Goldman Sachs | Goldman Sachs | Buy Initiates $44 | Buy | Initiates | $44 | +52.46% | Jul 13, 2026 |
| Needham | Needham | Buy Maintains $40 | Buy | Maintains | $40 | +38.60% | Jul 9, 2026 |
Unknown Analyst Jefferies No rating | Jefferies | Buy Maintains $39 → $48 | Buy | Maintains | $39 → $48 | +66.32% | Jul 6, 2026 |
| Leerink Partners | Leerink Partners | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Jun 2, 2026 |
| BTIG | BTIG | Buy Maintains $39 | Buy | Maintains | $39 | +35.14% | May 11, 2026 |
Financial Forecast
Revenue This Year
24.32M
from 184.42M
Decreased by -86.81%
Revenue Next Year
46.50M
from 24.32M
Increased by 91.23%
EPS This Year
-3.29
from -0.12
EPS Next Year
-3.09
from -3.29
EPS and Forward PE are based on non-GAAP adjusted numbers.